Analyst Ratings For NASDAQ:RVNC – Revance Therapeutics (NASDAQ:RVNC)
Today, Mizuho lowered its price target on NASDAQ:RVNC – Revance Therapeutics (NASDAQ:RVNC) to $48.00 per share.
Some recent analyst ratings include
- 4/2/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 3/26/2018-Needham & Company LLC initiated coverage with a Buy rating.
- 3/5/2018-Goldman Sachs initiated coverage with a Buy rating.
- 3/1/2018-William Blair Reiterated Rating of Outperform.
Recent Insider Trading Activity For NASDAQ:RVNC – Revance Therapeutics (NASDAQ:RVNC)
NASDAQ:RVNC – Revance Therapeutics (NASDAQ:RVNC) has insider ownership of 18.86% and institutional ownership of 95.01%.
- On 3/22/2018 Lauren P Silvernail, CFO, sold 3,431 with an average share price of $30.85 per share and the total transaction amounting to $105,846.35.
- On 3/16/2018 L Daniel Browne, CEO, sold 6,452 with an average share price of $31.64 per share and the total transaction amounting to $204,141.28.
- On 3/16/2018 Phyllis Gardner, Director, sold 5,333 with an average share price of $31.51 per share and the total transaction amounting to $168,042.83.
- On 3/13/2018 Lauren P Silvernail, CFO, sold 25,867 with an average share price of $34.50 per share and the total transaction amounting to $892,411.50.
- On 3/9/2018 Lauren P Silvernail, CFO, sold 20,000 with an average share price of $32.00 per share and the total transaction amounting to $640,000.00.
- On 3/7/2018 L Daniel Browne, CEO, sold 27,283 with an average share price of $31.43 per share and the total transaction amounting to $857,504.69.
- On 3/7/2018 Lauren P Silvernail, CFO, sold 10,000 with an average share price of $31.50 per share and the total transaction amounting to $315,000.00.
Recent Trading Activity for NASDAQ:RVNC – Revance Therapeutics (NASDAQ:RVNC)
Shares of NASDAQ:RVNC – Revance Therapeutics closed the previous trading session at 31.35 down -2.00 6.00% with 33.20000076293945 shares trading hands.